Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
Aug 15 |
VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript
|
Aug 15 |
VolitionRX reports Q2 results
|
Aug 14 |
VolitionRX: Q2 Earnings Snapshot
|
Aug 14 |
VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
|
Aug 14 |
VolitionRX Q2 2024 Earnings Preview
|
Aug 6 |
VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
|
Jul 9 |
Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
|
Jun 27 |
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
|
Jun 25 |
VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Distribution of Nu.Q Vet Test Expected to Expand During 2H 2024; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture-PCR) 2) Nu.Q NET for Sepsis
|